NADPH Oxidase Inhibition in Fibrotic Pathologies
NADPH Oxidase Inhibition in Fibrotic Pathologies
复制标题
DOI：
10.1089/ars.2020.8032
复制
发表时间：
2020-03-04
影响因子：
6.6
通讯作者：
Thannickal, Victor J.
中科院分区：
文献类型：
--
作者：
Bernard, Karen;Thannickal, Victor J.
最新进展：有新的证据表明，遗传、环境和年龄相关的危险因素共同作用于不同器官系统的纤维化易感性和/或进展。涉及这些器官的纤维化形成的一个核心途径是烟酰胺腺嘌呤二核苷酸磷酸氧化酶(NOX)家族酶的诱导和激活。关键问题：我们探索了目前针对NOX酶的药物治疗方法，包括改变目前美国食品和药物管理局(FDA)批准的药物的用途。不同NOx同系物的特异性抑制剂将有助于确定NOx在各种器官纤维化中的作用和阻止/阻止疾病进展的潜在疗效。未来方向：新型和高度特异性的NOx抑制剂的发现将为开发治疗纤维化病理的NOx抑制剂提供机会。
Recent Advances: There is emerging evidence to support a combination of genetic, environmental, and age-related risk factors contributing to susceptibility and/or progression of fibrosis in different organ systems. A core pathway in fibrogenesis involving these organs is the induction and activation of nicotinamide adenine dinucleotide phosphate oxidase (NOX) family enzymes.Critical Issues: We explore current pharmaceutical approaches to targeting NOX enzymes, including repurposing of currently U.S. Food and Drug Administration (FDA)-approved drugs. Specific inhibitors of various NOX homologs will aid establishing roles of NOXs in the various organ fibroses and potential efficacy to impede/halt disease progression.Future Directions: The discovery of novel and highly specific NOX inhibitors will provide opportunities to develop NOX inhibitors for treatment of fibrotic pathologies.